Bugworks Research, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2014-02-04
- Employees
- 11
- Market Cap
- -
Clinical Trials
3
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)A Phase 1 Study of the Safety and Tolerability of Single and Multiple Ascending Doses of BWC0977 in Healthy Volunteers
Phase 1
Not yet recruiting
- Conditions
- Infectious DiseasesAntimicrobial Drug Resistance
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-06-19
- Last Posted Date
- 2025-09-19
- Lead Sponsor
- Bugworks Research Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT07029932
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
The Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of BWC0977 in Healthy Adult Volunteers
Phase 1
Terminated
- Conditions
- Bacterial InfectionsInfectious Diseases
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Bugworks Research Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT05942820
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia
A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of BWC0977 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Bacterial InfectionsInfectious Diseases
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Bugworks Research Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT05088421
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia
News
No news found